Thérapeutiques moléculaires ciblées en oncologie ORL
作者： C. Le Tourneau
关键词: Head and neck cancer 、 Targeted therapy 、 Monoclonal antibody 、 Cancer research 、 Cancer 、 Cetuximab 、 Adenoid cystic carcinoma 、 Nasopharyngeal carcinoma 、 Head and neck squamous-cell carcinoma 、 Pathology 、 Medicine
摘要: The emergence of molecularly targeted therapy did not spare head and neck cancers. Head squamous cell carcinomas (HNSCC) were indeed one the first tumor types to get a agent approved (cetuximab, monoclonal antibody targeting EGFR), only in recurrent or metastatic setting but also locally advanced setting. However, development agents inhibiting non-EGFR targets appears be complex. This article summarizes recent data on most frequent cancers including HNSCC, nasopharyngeal carcinoma adenoid cystic salivary glands. Challenges for these are then discussed.
sci-hub.se 参考文章(63)
J. Gilbert, J. Lee, A. Argiris, L. Feldman, M. Haigentz, B. Burtness, A. Forastiere, Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology. ,vol. 27, pp. 6020- 6020 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.6020
J. H. Machiels, S. Henry, S. Zanetta, M. Kaminsky, N. Michoux, E. Bompas, A. Dillies, S. Faivre, S. Schmitz, J. Guigay, Phase II study of sunitinib in patients with recurrent and/or metastatic squamous head and neck carcinoma : The GORTEC 2006-01 study Journal of Clinical Oncology. ,vol. 28, pp. 21- 28 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.6024
B. S. Glisson, G. Blumenschein, M. Francisco, J. Erasmus, R. Zinner, M. Kies, Phase II trial of gefitinib in patients with incurable salivary gland cancer Journal of Clinical Oncology. ,vol. 23, pp. 5532- 5532 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.5532
B. You, C. Le Tourneau, E.X. Chen, S.F. Chin, L. Wang, A. Jarvi, R.R. Bharadwaj, S. Kamel-Reid, B. Perez-Ordonez, L.L. Siu, 8527 A phase II trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and/or metastatic nasopharyngeal carcinoma (NPC) Ejc Supplements. ,vol. 7, pp. 478- 479 ,(2009) , 10.1016/S1359-6349(09)71618-0
M. Persson, Y. Andren, J. Mark, H. M. Horlings, F. Persson, G. Stenman, Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 18740- 18744 ,(2009) , 10.1073/PNAS.0909114106
George R. Blumenschein, Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Charles Lu, Ashok J. Kumar, Justin L. Ricker, Judy H. Chiao, Cong Chen, Stanley R. Frankel, Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer Investigational New Drugs. ,vol. 26, pp. 81- 87 ,(2008) , 10.1007/S10637-007-9075-2
Christine Elser, Lillian L. Siu, Eric Winquist, Mark Agulnik, Gregory R. Pond, Soo F. Chin, Peggy Francis, Robin Cheiken, James Elting, Angela McNabola, Dean Wilkie, Oana Petrenciuc, Eric X. Chen, Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma Journal of Clinical Oncology. ,vol. 25, pp. 3766- 3773 ,(2007) , 10.1200/JCO.2006.10.2871
Athanassios Argiris, Ezra Cohen, Theodore Karrison, Benjamin Esparaz, Ann Mauer, Rafat Ansari, Stuart Wong, Yi Lu, Michael Pins, Janet Dancey, Everett Vokes, A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer Cancer Biology & Therapy. ,vol. 5, pp. 766- 770 ,(2006) , 10.4161/CBT.5.7.2874
Brigette Ma, Edwin P. Hui, Ann King, K. F. To, Frankie Mo, Sing F. Leung, Michael Kam, Y. M. Dennis Lo, Benny Zee, Tony Mok, Anil Ahuja, Anthony T. C. Chan, A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemotherapy and Pharmacology. ,vol. 62, pp. 59- 64 ,(2008) , 10.1007/S00280-007-0575-8
Carter Van Waes, Angela A. Chang, Peter F. Lebowitz, Colleen H. Druzgal, Zhong Chen, Yusri A. Elsayed, John B. Sunwoo, Susan F. Rudy, John C. Morris, James B. Mitchell, Kevin Camphausen, David Gius, Julian Adams, Edward A. Sausville, Barbara A. Conley, Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma International Journal of Radiation Oncology Biology Physics. ,vol. 63, pp. 1400- 1412 ,(2005) , 10.1016/J.IJROBP.2005.05.007